Home » Stocks » LogicBio Therapeutics

LogicBio Therapeutics, Inc. (LOGC)

Stock Price: $5.64 USD -0.11 (-1.91%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 133.60M
Revenue (ttm) 1.99M
Net Income (ttm) -40.07M
Shares Out 23.69M
EPS (ttm) -1.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $5.64
Previous Close $5.75
Change ($) -0.11
Change (%) -1.91%
Day's Open 5.75
Day's Range 5.50 - 5.87
Day's Volume 150,130
52-Week Range 3.05 - 11.60

More Stats

Market Cap 133.60M
Enterprise Value 112.59M
Earnings Date (est) Dec 7, 2020
Ex-Dividend Date n/a
Shares Outstanding 23.69M
Float 17.34M
EPS (basic) -1.75
EPS (diluted) -1.74
FCF / Share -1.65
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 486,640
Short Ratio 2.44
Short % of Float 2.81%
Beta 0.99
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 67.27
PB Ratio 6.48
Revenue 1.99M
Operating Income -39.77M
Net Income -40.07M
Free Cash Flow -38.50M
Net Cash 21.01M
Net Cash / Share 0.89
Gross Margin 100.00%
Operating Margin -2,002.42%
Profit Margin -2,017.40%
FCF Margin -1,938.62%
ROA -43.09%
ROE -87.51%
ROIC -165.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(290.07% upside)
Current: $5.64
Target: 22.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-41.04-17.94-5.85-3.40
Net Income-40.13-17.62-7.74-3.77
Shares Outstanding22.605.801.400.85
Earnings Per Share-1.78-3.04-5.54-4.43
Operating Cash Flow-38.75-15.27-5.78-2.37
Capital Expenditures-1.42-0.58-0.04-0.23
Free Cash Flow-40.17-15.85-5.82-2.60
Cash & Equivalents51.4281.0524.581.73
Total Debt10.31---
Net Cash / Debt41.1081.0524.581.73
Book Value42.2980.23-8.60-3.25
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name LogicBio Therapeutics, Inc.
Country United States
Employees 41
CEO Frédéric Chéreau

Stock Information

Ticker Symbol LOGC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LOGC
IPO Date October 19, 2018


LogicBio Therapeutics, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Lexington, Massachusetts.